How long before I know if PEA works?

Eight weeks at 1200 mg daily. Responders usually notice change between weeks four and eight.

Does it work for all nerve pain?

No. Trials in sciatica and diabetic neuropathy are positive, but the linked trial in spinal cord injury pain found no benefit.

Is PEA a cannabinoid?

No. It raises endocannabinoid tone indirectly but does not bind CB1, so it is not psychoactive.

Can I take it with pregabalin?

There is no known metabolic interaction, but do not change a prescribed dose without your prescriber.

Does the formulation matter?

Yes. Trials used micronised or ultramicronised PEA because plain powder absorbs poorly.

Condition

Moderate Evidence

Effectiveness 4/5

PEA for Nerve Pain (Neuropathy)

PEA reduces neuropathic pain by roughly 1.5 to 2 points on a 10-point scale in pooled trials, with an adverse event profile indistinguishable from placebo.

Overview

Palmitoylethanolamide is an endogenous fatty acid amide the body produces in response to tissue injury, and it has been marketed for neuropathic pain on the strength of Italian trials in sciatica and diabetic neuropathy that reported meaningful reductions in pain scores at 600 to 1200 mg daily. The mechanism is plausible: PEA damps down glial and mast cell activation rather than acting on opioid receptors, so it does not sedate or create dependence. The honest position is that the evidence is uneven. The one randomised trial linked to this pairing tested ultramicronised PEA in spinal cord injury neuropathic pain and found no advantage over placebo. Positive results cluster in compression and metabolic neuropathies; central neuropathic pain has not responded. Treat PEA as a low-risk adjunct worth an eight week trial, not as a reliable analgesic.

Verdict

Likely effective

Randomised evidence is split. Peripheral and compressive neuropathies show benefit in several trials at 600 to 1200 mg daily; central neuropathic pain after spinal cord injury showed none. Safety is excellent, which is why an individual trial is reasonable.

Pain type matters more than dose

The linked trial that failed used the same ultramicronised formulation and a standard dose. The difference was the pain generator: central cord injury rather than a compressed or metabolically damaged peripheral nerve.

How It Works

PEA is produced on demand from membrane phospholipids at sites of injury and acts mainly through PPAR-alpha activation inside glia and mast cells. That switches off transcription of inflammatory mediators which sensitise nociceptors, so the effect is on the amplifier rather than on the nerve signal itself. A second route is the so-called entourage effect: PEA competes for the enzymes that degrade anandamide, indirectly raising endocannabinoid tone at CB1 and CB2 receptors without binding them. This explains why PEA lacks the psychoactivity of cannabinoids, and also why its ceiling of effect is modest. Ultramicronised and micronised particle sizes exist because unformulated PEA dissolves poorly and absorbs erratically.

Pathways involved

PPAR-alpha activation

Mast cell stabilisation

Microglial downregulation

Indirect endocannabinoid tone

Reduced peripheral sensitisation

Dosing & Protocol

Scenario	Dose	Form	Timing
Standard trial dose	600 mg twice daily	Ultramicronised (um-PEA)	Away from large meals
Maintenance after response	600 mg once daily	Ultramicronised or micronised	Morning
Loading period	1200 mg daily for 4 to 8 weeks	Ultramicronised	Split into two doses
Ceiling in trials	1800 mg daily	Any	Divided

1
Use a micronised formulation· From the start
Trials used ultramicronised or micronised PEA. Unformulated bulk powder has not been shown to reproduce those results.
2
Run 1200 mg daily for eight weeks· Weeks 1 to 8
Most responders in published trials improved between weeks four and eight. Shorter trials are not informative.
3
Score pain the same way each week· Weekly
A 0 to 10 numeric scale recorded at the same time of day, plus a note on night waking, is enough to see a real change.
4
Halve the dose if you respond· Week 8 onward
Responders in open extensions maintained on 600 mg daily.
5
Stop if nothing changes by week eight· Week 8
PEA is not a slow accumulator beyond this point, and continuing costs money without benefit.

Formulation is not interchangeable

Particle size drives absorption. Products that do not state micronised or ultramicronised on the label are not the material used in the trials.

Dosing in the literature is remarkably consistent: 1200 mg daily during an initial phase, usually split into two 600 mg doses, then a step down to 600 mg for maintenance. Nothing suggests going higher improves response, and there is no evidence for pulsed or as-needed use.

Evidence

The randomised trial linked to this pairing enrolled 73 people with neuropathic pain after spinal cord injury and compared ultramicronised PEA with placebo over twelve weeks. Pain intensity fell in both groups and the difference between them was not significant, which is a clean negative result in a reasonably sized, properly blinded study. The wider literature is more favourable but weaker in design. Trials in sciatic pain and diabetic peripheral neuropathy, largely conducted in Italy and often industry supported, report reductions of roughly two points on a ten point scale. The pattern across the field is that peripheral, inflammatory or compressive pain responds while central pain does not, and until that is tested directly it remains an inference rather than an established rule.

Studies linked to this pairing.

Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial

Score: 9/10

2016

rct

n=73

Andresen SR, Bing J, Hansen RM +7 more

Ultramicronized PEA did not reduce neuropathic pain intensity more than placebo

View source

Best linked evidence: Randomised placebo-controlled trial in 73 people with spinal cord injury pain
Linked result: No significant benefit over placebo
Wider literature: Benefit reported in sciatica and diabetic neuropathy trials
Studied dose: 1200 mg daily reducing to 600 mg
Certainty: Low to moderate, with clear heterogeneity by pain type

Safety

PEA has one of the cleaner safety records among pain supplements. Across trials adverse events occurred at roughly placebo rates, with mild gastrointestinal upset the most common complaint, and no signal for sedation, dependence, liver or kidney effects at doses up to 1800 mg daily for several months. The main risk is indirect. Neuropathic pain can be the presenting sign of an untreated cause such as B12 deficiency, uncontrolled diabetes, spinal compression or a compressive tumour, and a supplement that partially masks symptoms can delay diagnosis. Anyone with new, worsening or asymmetric nerve pain needs a clinical assessment first.

Investigate the cause first

New or progressive nerve pain, especially with weakness or bladder changes, is a reason to see a clinician the same week rather than to start a supplement.

Reported effects

Mild nausea

Stomach discomfort

Occasional drowsiness

No dependence signal

Safety in pregnancy not established

Interactions & Conflicts

PEA is not a substrate for the major cytochrome P450 enzymes and has no documented pharmacokinetic interactions, so the concerns are practical rather than metabolic: additive drowsiness, and the temptation to reduce prescribed neuropathic pain medication without supervision.

Interacts with	Severity	Mechanism	Action
Gabapentin and pregabalin	low	Both act on neuronal excitability; additive sedation is possible	Combine cautiously and do not reduce the prescription without your prescriber
Duloxetine and amitriptyline	low	No known metabolic interaction; overlapping side effect profile	Watch for extra drowsiness in the first fortnight
Opioid analgesics	moderate	Different receptors, but combined use can mask escalation of the underlying problem	Manage tapering only with the prescribing clinician
Pregnancy and breastfeeding	moderate	No adequate safety data	Avoid

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.